Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Medicine Matters rheumatology

  • Children with rheumatic diseases using immunosuppressive drugs are more susceptible to vaccine-preventable infections.
  • It is important to plan biologic immunosuppressive therapy around live vaccination.
  • Vaccination coverage of the general public has shown a steady decline over recent years.
  • Public health authorities must address the concerns of the general public in order to improve vaccination coverage